15.9.2010

Amendment 351
Sabine Wils
on behalf of the GUE/NGL Group

Report
Christa Klaß
Placing on the market and use of biocidal products

Proposal for a regulation
Article 3 – paragraph 1 – point u a (new)

Text proposed by the Commission

(ua) "risk mitigation measures" means measures that minimise the potential risks of the use of active substances or products on humans, non-targeted animals and the environment. Such measures especially include preventive risk reduction measures, monitoring, maximum residue values and provisions to limit the application of highly hazardous products to certified professional users;

Or. en

Justification

Clarification. Risks reduction measures shall contribute to adequately reduce the risks of biocides in order to protect human and animal health and the environment.
15.9.2010 A7-0239/352

Amendment 352
Sabine Wils
on behalf of the GUE/NGL Group

Report A7-0239/2010
Christa Klaß
Placing on the market and use of biocidal products

Proposal for a regulation
Article 3 – paragraph 1 – point u b (new)

Text proposed by the Commission

(ub) "normal conditions of use" means foreseeable uses of an active substance or product throughout its entire life cycle, including disposal and taking into account realistic worst-case situations such as improper use and accidents.

Or. en

Justification

It is necessary to ensure that the whole life cycle of a biocide will be considered, including disposal.
15.9.2010 A7-0239/353

Amendment 353
Sabine Wils
on behalf of the GUE/NGL Group

Report A7-0239/2010
Christa Klaß
Placing on the market and use of biocidal products

Proposal for a regulation
Article 21 – paragraph 4

Text proposed by the Commission

Amendment

4. By way of derogation from paragraph 1, a biocidal product containing an active substance that is a candidate for substitution shall be authorised without comparative assessment in cases where it is necessary to acquire experience first through using that product in practice.

deleted

Or. en

Justification

When a substance is classified as a candidate for substitution it is established that there are health and environmental hazards associated with it. Products with candidates for substitution should therefore always undergo comparative assessment before being placed on the market.
Amendment 354
Sabine Wils
on behalf of the GUE/NGL Group

Report
Christa Klaß
Placing on the market and use of biocidal products

Proposal for a regulation
Annex IV – introductory part

Text proposed by the Commission

The applicant may propose to adapt the data requirements set out in Annexes II and III according to the general rules set out in this Annex. The reasons for such adaptations to the data requirements must be clearly stated under the appropriate heading of the dossier referring to the specific rule(s) of this Annex.

Amendment

The applicant may propose to adapt the data requirements set out in Annexes II and III according to the general rules set out in this Annex. The reasons for such adaptations to the data requirements must be clearly stated under the appropriate heading of the dossier referring to the specific rule(s) of this Annex and must be based on sufficient scientific grounds and be confirmed by the competent authority.

Or. en

Justification

Annex IV is not adequate enough in order to ensure sufficient data gathering in line with this Regulation.
15.9.2010

Amendment 355
Sabine Wils
on behalf of the GUE/NGL Group

Report
Christa Klaß
Placing on the market and use of biocidal products

Proposal for a regulation
Article 70 – paragraph 2 – point a

Text proposed by the Commission
(a) a reduced fee shall be set for small and medium-sized enterprises within the meaning of Recommendation 2003/361/EC concerning the definition of micro, small and medium-sized enterprises;

Amendment
(a) reduced fees shall be set for small and medium-sized enterprises within the meaning of Recommendation 2003/361/EC concerning the definition of micro, small and medium-sized enterprises; in particular, micro and small-sized enterprises shall receive a significant reduction in the annual fee;

Or. en

Justification

The annual fee should be maintained to ensure adequate funding of ECHA, which has to provide continuous work on biocides. That work has to be done irrespective of the size of the applicant. This is all the more important if the scope of central authorisation and thus the resources required for ECHA are to increase significantly. However, to account for the special situation of micro and small enterprises, a significant reduction of the annual fee for them should be laid down explicitly.